Avai Bio (AVAI) Shares Outstanding (Weighted Average) (2018 - 2025)

Avai Bio has disclosed Shares Outstanding (Weighted Average) across 8 years of filings, most recently posting $137.7 million for Q4 2025.

• Shares Outstanding (Weighted Average) for Q4 2025 came in at $137.7 million, up 10.01% year-over-year; the trailing twelve-month figure through Dec 2025 was $137.7 million (up 10.01% YoY), and the FY2025 annual result was $128.1 million, up 48.09% from the prior year.
• Shares Outstanding (Weighted Average) came in at $137.7 million for Q4 2025 at Avai Bio, roughly flat from $137.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $137.7 million in Q4 2025 to a low of $26.3 million in Q1 2021.
• The 5-year median for Shares Outstanding (Weighted Average) is $62.4 million (2023), against an average of $72.6 million.
• Peak annual rise in Shares Outstanding (Weighted Average) reached 2482.97% in 2021, while the deepest fall reached 0.0% in 2021.
• Avai Bio's Shares Outstanding (Weighted Average) stood at $26.3 million in 2021, then advanced by 22.48% to $32.2 million in 2022, then surged by 108.11% to $67.1 million in 2023, then soared by 86.62% to $125.2 million in 2024, then rose by 10.01% to $137.7 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $137.7 million (Q4 2025), $137.5 million (Q3 2025), and $137.5 million (Q2 2025), per Business Quant data.